A method of diagnosing pancreatic cancer based on lipidomic analysis of a serum taken from the body of a human patient, characterized in that it comprises the steps of: - spiking of the sample with a set of internal standards comprising at least one internal standard for each lipid class present in the sample, - subsequently processing the sample by liquid-liquid lipidomic extraction, - measurement of the processed sample by a mass spectrometry method, - determining concentrations for at least 60, preferably at least 120 or at least 230, more preferably for all lipids present at a level above detection threshold of the mass spectrometry method, using the internal standards for the corresponding lipid classes for the quantitation, or using relative concentrations of lipids, or using ratios of concentrations and/or signal intensities, wherein the lipids for which the concentrations are determined include the following lipids: HexCer d18:1/16:0; HexCer d18:1/15:1 SM 34:1 HexCer d18:1/24:1; HexCer d18:1/23:2 PE 34:1; PE P-35:0 PC 32:0; PC O-33:0 PE 36:4; PE P-37:3 PC 34:1; PC P-35:0 PE 34:2; PE P-35:1 PC P-34:0; PC 33:1 DG 36:2 Cer d18:1/24:1; Cer d18:1/23:2 CE 16:0 SM 41:1 SM 41:2 PC 34:4; PC P-35:3 HexCer d18:1/24:0; HexCer d18:1/23:1 PE P-36:3; PE 35:4 PE P-38:4; PE 37:5 PE P-38:5; PE 37:6 PE P-36:2; PE 35:3 SM 32:1 HexCer d18:1/22:0; HexCer d18:1/21:1 PE P-38:3; PE 37:4 PC P-38:2; PC 37:3 PE P-40:5; PE 39:6 PE 36:0; PE P-38:6 PE 38:0; PE P-40:6, PE O-39:0 PE P-36:3; PE 35:4 PC P-34:1; PC 33:2 - statistical evaluation of the determined concentrations of the lipids, said statistical evaluation determining the level of probability of the patient suffering from pancreatic cancer based on the determined lipid concentrations compared to a cancerous pattern and a non-cancerous pattern, wherein the cancerous pattern and the non-cancerous pattern are determined by statistical analysis of the lipid concentrations for a group of known cancer samples and non-cancer samples, wherein the statistical evaluation is done separately for males and females. - spiking of the sample with a set of internal standards comprising at least one internal standard for each lipid class present in the sample, - subsequently processing the sample by liquid-liquid lipidomic extraction, - measurement of the processed sample by a mass spectrometry method, - determining concentrations for at least 60, preferably at least 120 or at least 230, more preferably for all lipids present at a level above detection threshold of the mass spectrometry method, using the internal standards for the corresponding lipid classes for the quantitation, or using relative concentrations of lipids, or using ratios of concentrations and/or signal intensities, HexCer d18:1/16:0; HexCer d18:1/15:1 SM 34:1 HexCer d18:1/24:1; HexCer d18:1/23:2 PE 34:1; PE P-35:0 PC 32:0; PC O-33:0 PE 36:4; PE P-37:3 PC 34:1; PC P-35:0 PE 34:2; PE P-35:1 PC P-34:0; PC 33:1 DG 36:2 Cer d18:1/24:1; Cer d18:1/23:2 CE 16:0 SM 41:1 SM 41:2 PC 34:4; PC P-35:3 HexCer d18:1/24:0; HexCer d18:1/23:1 PE P-36:3; PE 35:4 PE P-38:4; PE 37:5 PE P-38:5; PE 37:6 PE P-36:2; PE 35:3 SM 32:1 HexCer d18:1/22:0; HexCer d18:1/21:1 PE P-38:3; PE 37:4 PC P-38:2; PC 37:3 PE P-40:5; PE 39:6 PE 36:0; PE P-38:6 PE 38:0; PE P-40:6, PE O-39:0 PE P-36:3; PE 35:4 PC P-34:1; PC 33:2 - statistical evaluation of the determined concentrations of the lipids, said statistical evaluation determining the level of probability of the patient suffering from pancreatic cancer based on the determined lipid concentrations compared to a cancerous pattern and a non-cancerous pattern, wherein the cancerous pattern and the non-cancerous pattern are determined by statistical analysis of the lipid concentrations for a group of known cancer samples and non-cancer samples, wherein the statistical evaluation is done separately for males and females. <EOS>